Stem definition | Drug id | CAS RN |
---|---|---|
dopaminergic agents dopamine derivatives used as cardiac stimulant/antihypertensives/diuretics | 947 | 51-61-6 |
Dose | Unit | Route |
---|---|---|
0.50 | g | P |
Property | Value | Reference |
---|---|---|
MRTD (Maximum Recommended Therapeutic Daily Dose) | 470 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Hosey CM, Chan R, Benet LZ |
Vd (Volume of distribution) | 0.74 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 65.90 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.87 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 0.42 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Feb. 25, 1974 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Multiple organ dysfunction syndrome | 92.68 | 25.26 | 52 | 3429 | 50285 | 50551358 |
Cardiac arrest | 64.14 | 25.26 | 50 | 3431 | 83601 | 50518042 |
Renal ischaemia | 62.24 | 25.26 | 13 | 3468 | 569 | 50601074 |
PCO2 increased | 53.51 | 25.26 | 13 | 3468 | 1130 | 50600513 |
PO2 increased | 52.37 | 25.26 | 12 | 3469 | 810 | 50600833 |
Blood bicarbonate decreased | 50.95 | 25.26 | 15 | 3466 | 2710 | 50598933 |
Hypotension | 50.56 | 25.26 | 71 | 3410 | 235398 | 50366245 |
Cardiogenic shock | 48.64 | 25.26 | 23 | 3458 | 15576 | 50586067 |
Diabetes insipidus | 48.57 | 25.26 | 14 | 3467 | 2350 | 50599293 |
Oxygen saturation abnormal | 46.72 | 25.26 | 14 | 3467 | 2688 | 50598955 |
Blood pH decreased | 43.66 | 25.26 | 13 | 3468 | 2442 | 50599201 |
Status epilepticus | 42.51 | 25.26 | 20 | 3461 | 13386 | 50588257 |
Ventricular tachycardia | 42.30 | 25.26 | 21 | 3460 | 15800 | 50585843 |
Foetal death | 41.54 | 25.26 | 17 | 3464 | 8163 | 50593480 |
Enzyme induction | 37.50 | 25.26 | 6 | 3475 | 56 | 50601587 |
Renal impairment | 37.04 | 25.26 | 35 | 3446 | 75626 | 50526017 |
Shock | 34.37 | 25.26 | 20 | 3461 | 20630 | 50581013 |
Renal injury | 34.10 | 25.26 | 15 | 3466 | 8596 | 50593047 |
Pulmonary oedema | 32.66 | 25.26 | 27 | 3454 | 48911 | 50552732 |
Newborn persistent pulmonary hypertension | 32.21 | 25.26 | 6 | 3475 | 144 | 50601499 |
Bradycardia | 31.90 | 25.26 | 30 | 3451 | 64396 | 50537247 |
Cardiopulmonary failure | 31.70 | 25.26 | 11 | 3470 | 3362 | 50598281 |
Cardiac assistance device user | 31.42 | 25.26 | 5 | 3476 | 45 | 50601598 |
Electroencephalogram abnormal | 31.30 | 25.26 | 11 | 3470 | 3488 | 50598155 |
Seizure | 30.50 | 25.26 | 39 | 3442 | 117835 | 50483808 |
Blood magnesium decreased | 30.38 | 25.26 | 15 | 3466 | 11145 | 50590498 |
Renal failure | 30.34 | 25.26 | 37 | 3444 | 106596 | 50495047 |
Disseminated intravascular coagulation | 29.59 | 25.26 | 17 | 3464 | 17118 | 50584525 |
Clonus | 29.40 | 25.26 | 11 | 3470 | 4164 | 50597479 |
Metabolic acidosis | 29.25 | 25.26 | 23 | 3458 | 38802 | 50562841 |
Drug ineffective | 28.42 | 25.26 | 121 | 3360 | 819212 | 49782431 |
Left ventricular dysfunction | 28.24 | 25.26 | 14 | 3467 | 10492 | 50591151 |
Blood pressure decreased | 27.61 | 25.26 | 26 | 3455 | 55883 | 50545760 |
Electrocardiogram QRS complex prolonged | 26.77 | 25.26 | 11 | 3470 | 5333 | 50596310 |
Systolic anterior motion of mitral valve | 26.42 | 25.26 | 4 | 3477 | 25 | 50601618 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Multiple organ dysfunction syndrome | 54.39 | 20.11 | 52 | 3630 | 63064 | 29507781 |
Drug ineffective | 48.21 | 20.11 | 125 | 3557 | 363045 | 29207800 |
Disseminated intravascular coagulation | 47.29 | 20.11 | 30 | 3652 | 19950 | 29550895 |
Ventricular fibrillation | 40.55 | 20.11 | 25 | 3657 | 15808 | 29555037 |
Hypotension | 39.08 | 20.11 | 79 | 3603 | 194275 | 29376570 |
Torsade de pointes | 38.27 | 20.11 | 18 | 3664 | 6643 | 29564202 |
Blood urea increased | 38.05 | 20.11 | 30 | 3652 | 28082 | 29542763 |
Shock | 29.30 | 20.11 | 23 | 3659 | 21381 | 29549464 |
Metabolic acidosis | 28.61 | 20.11 | 29 | 3653 | 37633 | 29533212 |
Acute kidney injury | 27.80 | 20.11 | 84 | 3598 | 265183 | 29305662 |
Cardiogenic shock | 27.08 | 20.11 | 21 | 3661 | 19169 | 29551676 |
Cardiac arrest | 25.03 | 20.11 | 41 | 3641 | 85550 | 29485295 |
Neutrophil count increased | 24.97 | 20.11 | 18 | 3664 | 14724 | 29556121 |
Lymphocyte count decreased | 24.85 | 20.11 | 20 | 3662 | 19251 | 29551594 |
Acidosis | 24.02 | 20.11 | 15 | 3667 | 9690 | 29561155 |
Dry gangrene | 22.94 | 20.11 | 6 | 3676 | 385 | 29570460 |
Respiratory failure | 22.51 | 20.11 | 42 | 3640 | 97089 | 29473756 |
Hypernatraemia | 22.37 | 20.11 | 13 | 3669 | 7373 | 29563472 |
Renal failure | 22.33 | 20.11 | 47 | 3635 | 118552 | 29452293 |
Incision site pain | 20.91 | 20.11 | 8 | 3674 | 1775 | 29569070 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Multiple organ dysfunction syndrome | 101.13 | 21.64 | 83 | 6447 | 101330 | 64390872 |
Hypotension | 74.69 | 21.64 | 136 | 6394 | 380838 | 64111364 |
Cardiac arrest | 73.39 | 21.64 | 84 | 6446 | 153980 | 64338222 |
Disseminated intravascular coagulation | 71.12 | 21.64 | 43 | 6487 | 32305 | 64459897 |
Cardiogenic shock | 65.91 | 21.64 | 41 | 6489 | 32386 | 64459816 |
Blood urea increased | 58.93 | 21.64 | 43 | 6487 | 44110 | 64448092 |
Ventricular fibrillation | 58.40 | 21.64 | 34 | 6496 | 23826 | 64468376 |
Drug ineffective | 57.95 | 21.64 | 201 | 6329 | 840046 | 63652156 |
Shock | 55.05 | 21.64 | 39 | 6491 | 38201 | 64454001 |
Ventricular tachycardia | 49.45 | 21.64 | 35 | 6495 | 34230 | 64457972 |
Renal ischaemia | 49.20 | 21.64 | 13 | 6517 | 1070 | 64491132 |
PCO2 increased | 48.04 | 21.64 | 14 | 6516 | 1653 | 64490549 |
Metabolic acidosis | 44.86 | 21.64 | 45 | 6485 | 70913 | 64421289 |
Diabetes insipidus | 41.34 | 21.64 | 16 | 6514 | 4505 | 64487697 |
Respiratory failure | 41.34 | 21.64 | 65 | 6465 | 161118 | 64331084 |
Septic shock | 41.14 | 21.64 | 52 | 6478 | 105385 | 64386817 |
PO2 increased | 40.66 | 21.64 | 12 | 6518 | 1480 | 64490722 |
Foetal death | 40.46 | 21.64 | 17 | 6513 | 5913 | 64486289 |
Blood pH decreased | 38.21 | 21.64 | 15 | 6515 | 4387 | 64487815 |
Oxygen saturation abnormal | 37.57 | 21.64 | 14 | 6516 | 3557 | 64488645 |
Blood bicarbonate decreased | 36.86 | 21.64 | 15 | 6515 | 4814 | 64487388 |
Acute kidney injury | 36.60 | 21.64 | 114 | 6416 | 449126 | 64043076 |
Renal impairment | 33.98 | 21.64 | 54 | 6476 | 134963 | 64357239 |
Renal failure | 33.11 | 21.64 | 63 | 6467 | 181625 | 64310577 |
Torsade de pointes | 32.88 | 21.64 | 21 | 6509 | 17342 | 64474860 |
Bradycardia | 32.14 | 21.64 | 49 | 6481 | 118170 | 64374032 |
Platelet count decreased | 31.60 | 21.64 | 59 | 6471 | 167652 | 64324550 |
Enzyme induction | 31.48 | 21.64 | 6 | 6524 | 109 | 64492093 |
Blood pressure decreased | 31.24 | 21.64 | 41 | 6489 | 86158 | 64406044 |
Pulmonary oedema | 30.99 | 21.64 | 39 | 6491 | 78635 | 64413567 |
Neutrophil count increased | 30.18 | 21.64 | 23 | 6507 | 25151 | 64467051 |
Acidosis | 29.97 | 21.64 | 20 | 6510 | 17775 | 64474427 |
Fatigue | 29.40 | 21.64 | 20 | 6510 | 748710 | 63743492 |
Hypernatraemia | 28.84 | 21.64 | 17 | 6513 | 12172 | 64480030 |
Status epilepticus | 28.66 | 21.64 | 21 | 6509 | 21642 | 64470560 |
Cardiac assistance device user | 28.02 | 21.64 | 5 | 6525 | 62 | 64492140 |
Sepsis | 27.18 | 21.64 | 67 | 6463 | 230274 | 64261928 |
Arthralgia | 26.83 | 21.64 | 6 | 6524 | 442254 | 64049948 |
Incision site pain | 26.44 | 21.64 | 10 | 6520 | 2644 | 64489558 |
Left ventricular dysfunction | 26.04 | 21.64 | 18 | 6512 | 16936 | 64475266 |
Seizure | 25.74 | 21.64 | 54 | 6476 | 166838 | 64325364 |
Systolic dysfunction | 24.62 | 21.64 | 10 | 6520 | 3192 | 64489010 |
Blood magnesium decreased | 24.31 | 21.64 | 16 | 6514 | 13889 | 64478313 |
Cardiac failure | 22.99 | 21.64 | 45 | 6485 | 132328 | 64359874 |
Electroencephalogram abnormal | 22.96 | 21.64 | 11 | 6519 | 5192 | 64487010 |
Hepatic function abnormal | 22.38 | 21.64 | 30 | 6500 | 64283 | 64427919 |
N-terminal prohormone brain natriuretic peptide | 22.17 | 21.64 | 4 | 6526 | 53 | 64492149 |
Systolic anterior motion of mitral valve | 22.17 | 21.64 | 4 | 6526 | 53 | 64492149 |
Urine output decreased | 21.85 | 21.64 | 16 | 6514 | 16476 | 64475726 |
None
Source | Code | Description |
---|---|---|
ATC | C01CA04 | CARDIOVASCULAR SYSTEM CARDIAC THERAPY CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES Adrenergic and dopaminergic agents |
FDA CS | M0003647 | Catecholamines |
FDA EPC | N0000175570 | Catecholamine |
MeSH PA | D002316 | Cardiotonic Agents |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D015259 | Dopamine Agents |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D020011 | Protective Agents |
MeSH PA | D013566 | Sympathomimetics |
CHEBI has role | CHEBI:35522 | beta-adrenergic agonists |
CHEBI has role | CHEBI:35524 | sympathomimetic |
CHEBI has role | CHEBI:38147 | cardiotonic drugs |
CHEBI has role | CHEBI:48560 | dopaminergic agents |
CHEBI has role | CHEBI:75771 | Mus musculus metabolites |
CHEBI has role | CHEBI:76971 | Escherichia coli metabolites |
CHEBI has role | CHEBI:77746 | Homo sapiens metabolite |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Low cardiac output syndrome | indication | 44088000 | |
Low blood pressure | indication | 45007003 | |
Decompensated cardiac failure | indication | 195111005 | |
Sinus bradycardia | off-label use | 49710005 | |
Acute nephropathy | off-label use | 58574008 | |
Tachyarrhythmia | contraindication | 6285003 | |
Hypovolemia | contraindication | 28560003 | |
Ventricular arrhythmia | contraindication | 44103008 | |
Acidosis | contraindication | 51387008 | |
Pheochromocytoma | contraindication | 302835009 | |
Hypoxia | contraindication | 389086002 | |
Occlusive Vascular Disease | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 8.96 | acidic |
pKa2 | 12.98 | acidic |
pKa3 | 10.61 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Beta-1 adrenergic receptor | GPCR | AGONIST | Ki | 5 | WOMBAT-PK | CHEMBL | |||
Beta-2 adrenergic receptor | GPCR | Kd | 4.19 | CHEMBL | |||||
D(1A) dopamine receptor | GPCR | AGONIST | Ki | 9 | WOMBAT-PK | ||||
D(2) dopamine receptor | GPCR | AGONIST | Ki | 9 | WOMBAT-PK | ||||
Sodium-dependent noradrenaline transporter | Transporter | IC50 | 8.18 | WOMBAT-PK | |||||
5-hydroxytryptamine receptor 1A | GPCR | Ki | 5.08 | PDSP | |||||
D(3) dopamine receptor | GPCR | AGONIST | Ki | 9 | WOMBAT-PK | ||||
D(1B) dopamine receptor | GPCR | AGONIST | Ki | 9 | WOMBAT-PK | ||||
Sodium-dependent dopamine transporter | Transporter | Ki | 5.19 | CHEMBL | |||||
D(4) dopamine receptor | GPCR | AGONIST | Ki | 9 | WOMBAT-PK | ||||
Trace amine-associated receptor 1 | GPCR | Ki | 6.38 | WOMBAT-PK | |||||
Melatonin receptor type 1A | GPCR | Ki | 5.15 | CHEMBL | |||||
Melatonin receptor type 1B | GPCR | Ki | 5.04 | CHEMBL | |||||
Lysine-specific demethylase 4E | Enzyme | IC50 | 5.52 | CHEMBL | |||||
Dopamine beta-hydroxylase | Enzyme | Km | 3 | WOMBAT-PK | |||||
FAD-linked sulfhydryl oxidase ALR | Enzyme | AC50 | 5.85 | CHEMBL | |||||
Alpha-synuclein | Transporter | IC50 | 6.28 | CHEMBL | |||||
D(2) dopamine receptor | GPCR | Ki | 8.35 | CHEMBL | |||||
Sodium-dependent dopamine transporter | Transporter | IC50 | 6.70 | CHEMBL | |||||
D(1A) dopamine receptor | GPCR | Ki | 8.15 | CHEMBL | |||||
Beta-1 adrenergic receptor | GPCR | Ki | 5 | CHEMBL | |||||
D(1A) dopamine receptor | GPCR | Ki | 6.82 | CHEMBL | |||||
D(2) dopamine receptor | GPCR | Ki | 8.74 | CHEMBL | |||||
Beta-2 adrenergic receptor | GPCR | Ki | 4.30 | CHEMBL | |||||
D(3) dopamine receptor | GPCR | Ki | 7.96 | CHEMBL | |||||
D(4) dopamine receptor | GPCR | EC50 | 8.62 | CHEMBL | |||||
Opioid receptor | GPCR | IC50 | 5.52 | CHEMBL | |||||
Adrenergic receptor alpha-2 | GPCR | Ki | 7.24 | CHEMBL | |||||
Dopamine receptor | GPCR | IC50 | 8.43 | CHEMBL | |||||
Dopamine receptor | GPCR | IC50 | 5.27 | CHEMBL | |||||
Adrenergic receptor alpha-1 | GPCR | Ki | 4.85 | CHEMBL | |||||
Adenylate cyclase | Enzyme | EC50 | 5.46 | CHEMBL | |||||
Adenosine A2b receptor | GPCR | Ki | 6.01 | CHEMBL | |||||
M18 aspartyl aminopeptidase | Enzyme | IC50 | 5.70 | CHEMBL |
ID | Source |
---|---|
4019733 | VUID |
N0000147825 | NUI |
D00633 | KEGG_DRUG |
62-31-7 | SECONDARY_CAS_RN |
4018656 | VANDF |
4019733 | VANDF |
C0013030 | UMLSCUI |
CHEBI:18243 | CHEBI |
LDP | PDB_CHEM_ID |
CHEMBL59 | ChEMBL_ID |
DB00988 | DRUGBANK_ID |
CHEMBL1557 | ChEMBL_ID |
D004298 | MESH_DESCRIPTOR_UI |
681 | PUBCHEM_CID |
2417 | INN_ID |
940 | IUPHAR_LIGAND_ID |
VTD58H1Z2X | UNII |
3628 | RXNORM |
3090 | MMSL |
4632 | MMSL |
6641 | MMSL |
d00216 | MMSL |
001787 | NDDF |
004721 | NDDF |
16257000 | SNOMEDCT_US |
412383006 | SNOMEDCT_US |
59187003 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Dopamine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9252 | INJECTION | 40 mg | INTRAVENOUS | ANDA | 16 sections |
Dopamine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9252 | INJECTION | 40 mg | INTRAVENOUS | ANDA | 16 sections |
Dopamine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9253 | INJECTION | 80 mg | INTRAVENOUS | ANDA | 16 sections |
Dopamine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9253 | INJECTION | 80 mg | INTRAVENOUS | ANDA | 16 sections |
Dopamine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9254 | INJECTION | 40 mg | INTRAVENOUS | ANDA | 16 sections |
Dopamine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9254 | INJECTION | 40 mg | INTRAVENOUS | ANDA | 16 sections |
Dopamine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9255 | INJECTION | 80 mg | INTRAVENOUS | ANDA | 16 sections |
Dopamine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9255 | INJECTION | 80 mg | INTRAVENOUS | ANDA | 16 sections |
MYOCARD-DX | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0264-1840 | INJECTION | 80 mg | INTRAVENOUS | EXPORT ONLY | 20 sections |
MYOCARD-DX | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0264-1880 | INJECTION | 800 mg | INTRAVENOUS | EXPORT ONLY | 20 sections |
Dopamine Hydrochloride and Dextrose | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0338-1005 | INJECTION, SOLUTION | 80 mg | INTRAVENOUS | NDA | 22 sections |
Dopamine Hydrochloride and Dextrose | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0338-1007 | INJECTION, SOLUTION | 160 mg | INTRAVENOUS | NDA | 22 sections |
Dopamine Hydrochloride and Dextrose | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0338-1009 | INJECTION, SOLUTION | 320 mg | INTRAVENOUS | NDA | 22 sections |
Dopamine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0404-9981 | INJECTION, SOLUTION, CONCENTRATE | 40 mg | INTRAVENOUS | NDA | 11 sections |
Dopamine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0404-9982 | INJECTION, SOLUTION, CONCENTRATE | 40 mg | INTRAVENOUS | NDA | 11 sections |
DOPamine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-5820 | INJECTION, SOLUTION, CONCENTRATE | 40 mg | INTRAVENOUS | NDA | 17 sections |
Dopamine Hydrochloride in Dextrose | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-7809 | INJECTION, SOLUTION | 1.60 mg | INTRAVENOUS | NDA | 25 sections |
Dopamine Hydrochloride in Dextrose | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-7810 | INJECTION, SOLUTION | 3.20 mg | INTRAVENOUS | NDA | 25 sections |
DOPamine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-9104 | INJECTION, SOLUTION, CONCENTRATE | 40 mg | INTRAVENOUS | NDA | 17 sections |
DOPAMINE HCI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1220 | INJECTION, SOLUTION, CONCENTRATE | 40 mg | INTRAVENOUS | NDA | 12 sections |
DOPAMINE HCI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1291 | INJECTION, SOLUTION, CONCENTRATE | 40 mg | INTRAVENOUS | NDA | 12 sections |
DOPAMINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1316 | INJECTION, SOLUTION | 1.60 mg | INTRAVENOUS | NDA | 13 sections |
DOPAMINE HCI IN 5% DEXTROSE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1458 | INJECTION, SOLUTION | 1.60 mg | INTRAVENOUS | NDA | 13 sections |
DOPAMINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1489 | INJECTION | 40 mg | INTRAVENOUS | ANDA | 11 sections |
DOPAMINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1490 | INJECTION | 40 mg | INTRAVENOUS | ANDA | 11 sections |
Dopamine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52584-104 | INJECTION, SOLUTION, CONCENTRATE | 40 mg | INTRAVENOUS | NDA | 11 sections |
Dopamine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52584-820 | INJECTION, SOLUTION, CONCENTRATE | 40 mg | INTRAVENOUS | NDA | 11 sections |
DOPamine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71872-7066 | INJECTION, SOLUTION, CONCENTRATE | 40 mg | INTRAVENOUS | NDA | 17 sections |